Singapore markets open in 6 hours 33 minutes

Avacta Group Plc (RTQ1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
1.1500+0.0200 (+1.77%)
As of 08:00AM CEST. Market open.
Full screen
Previous close1.1300
Open1.1500
Bid1.1200 x N/A
Ask1.2300 x N/A
Day's range1.1500 - 1.1500
52-week range0.4780 - 1.5900
Volume350
Avg. volume5
Market cap295.167M
Beta (5Y monthly)1.79
PE ratio (TTM)N/A
EPS (TTM)-0.1230
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration

    LONDON & WETHERBY, England, September 05, 2022--Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.

  • Business Wire

    LG Chem Renews License Triggering Payment to Avacta

    LONDON & WETHERBY, England, June 30, 2022--Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, has exercised its renewal option as part of the ongoing collaboration with Avacta, triggering a license renewal fee payment to Avacta of $2 m

  • Business Wire

    Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake

    CAMBRIDGE & WETHERBY, England, April 13, 2022--Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, is pleased to announce that a milestone equity payment has been triggered resulting in an increase in Avacta’s shareholding in AffyXell Therapeutics ("AffyXell"), a joint venture between Avacta and Daewoong Pharmaceutical ("Daewoong") in South Korea.